Question 23 0 points Save Answer COVID-19 is associated with diffuse lung disease. Glucocorticoids may modulate inflammation-mediated lung injury and thereby reduce progression to respiratory failure and death. In this randomized controlled trial, the researcher randomly assigned patients to receive oral or intravenous dexamethasone (at a dose of 6 mg once daily) for up to 10 days or to receive usual care alone. A total of 2104 patients were assigned to receive dexamethasone and 4321 to receive usual care. Overall, 482 patients (22.9%) in the dexamethasone group and 1110 patients (25.7%) in the usual care group died within 28 days after randomization. Which is the most correct conclusion regarding the efficacy of the dexamethasone in terms of mortality? O A. The mortality rate in the dexamethasone is 25.7% O B. The efficacy of the dexamethasone is 10.9% O C. Based on the data provided, the dexamethasone has no efficacy O D. The efficacy of the dexamethasone is 12.2%